Long before beingidentified as PPARα agonists,fibrates were clinically prescribed for treatment of dyslipidemia.Subsequently, TZDs, structural analogues of fibrates, were shown to selectivelyactivate PPARγ [7, 9–11]. This evidence concerns the gene PPARA and metabolic syndrome.